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Abstract: Lowering IOP is the most readily modiﬁ  able risk factor to delay the development and 
progression of glaucoma (POAG). The ﬁ  xed combination of brimonidine tartrate 0.2% and timolol 
maleate 0.5% (FCBT) combines a highly selective α2-adrenergic agonist (brimonidine) with a 
non-selective β-blocker (timolol). FCBT reduces aqueous production and enhances uveoscleral 
outﬂ  ow. Concomitant brimonidine and timolol have additive effects on reducing intraocular 
pressure (IOP). Multi-center randomized control trials have documented superiority of FCBT 
twice daily on IOP control compared with monotherapy with the individual components, and equal 
efﬁ  cacy compared with concomitant therapy. IOP reduction with FCBT versus ﬁ  xed combination 
dorzolamide 2% and timolol 0.5% (FCDT) was similar in a small study. Other studies (n   293) 
evaluating concomitant brimonidine and timolol have shown that it is not inferior to FCDT. 
However, concomitant brimonidine and timolol administered twice daily was signiﬁ  cantly less 
efﬁ  cacious in IOP reduction than ﬁ  xed combination latanoprost 0.005% and timolol 0.5% (FCLT). 
There are no published studies comparing FCBT with FCLT. The side effect proﬁ  le for FCBT 
reﬂ  ects that of its individual components. FCBT was generally well tolerated, with less ocular 
side effects than brimondine alone, but more than timolol alone. Documented systemic effects 
were few, although this could be confounded by selection bias. FCBT is a safe and effective IOP 
lowering agent for POAG and ocular hypertension.
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Several studies have highlighted the impact of glaucoma as a leading cause of blindness 
(Thylefors and Negrel 1994; Quigley 1996). The estimated number of people with 
vision loss from glaucoma range from 5.2 (Thylefors and Negrel 1994) to 6.7 million. 
This is approximately 10% of the total number of affected persons, ranking glaucoma 
as the second most common cause of world blindness (Quigley 1996). Primary open-
angle glaucoma (POAG) is a progressive optic neuropathy with corresponding optic 
disc cupping and glaucomatous visual ﬁ  eld defects. The intraocular pressure (IOP) of 
the eye often exceeds its tolerance. Data from the Early Manifest Glaucoma trial (Heijl 
et al 2002) have shown that an additional 1 mmHg of IOP lowering reduces the risk 
of glaucoma progression by 10%. Participants of the Advanced Glaucoma Interven-
tion Study (AGIS-7 2000) who achieved the target IOP of  18 mmHg at each visit 
had minimal deterioration of visual ﬁ  eld over 96 months. Lowering IOP remains the 
most readily modiﬁ  able risk factor to delay development of glaucoma in subjects with 
ocular hypertension (OH) and progression of POAG (Kass et al 2002).
Several classes of topical IOP-lowering agents are available. These include β-receptor 
antagonists (selective or nonselective), prostaglandin F2α-analogs and prostamides, 
α-adrenergic agonists, carbonic anhydrase inhibitors, and cholinergic agents. 
Pharmacotherapy usually begins with a single topical agent (monotherapy), traditionally Clinical Ophthalmology 2008:2(3) 546
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a β-blocker. Since the introduction of prostaglandin analogues, 
many ophthalmologists prefer this agent as ﬁ  rst-line treatment 
(Schwartz and Budenz 2004). Subsequent addition of a second 
agent (combination therapy) or more is often required to 
achieve target pressures. In the Ocular Hypertension Treatment 
Study, 40% of treated subjects required  1 medication to 
achieve the therapeutic goal of 20% IOP reduction from 
baseline (Kass et al 2002). More than 75% of subjects in the 
medical treatment arm of the Collaborative Initial Glaucoma 
Treatment Study (Lichter et al 2001) required  2 medications 
after 2 years. One in two patients commenced on initial 
monotherapy will require additional ocular hypotensives 
within 2 years to control IOP (Kobelt-Nguyen et al 1998).
Modern adjunctive therapy combines a β-blocker with 
another class of drug such as a topical carbonic anhydrase 
inhibitor, prostaglandin analogue, or selective α-agonist 
(Fechtner and Realini 2004). For example, timolol 0.5% is 
combined as an invariant with dorzolamide 2% (Cosopt®, 
Merck and Co, Inc., Whitehouse Station, NJ, USA), latano-
prost 0.005% (Xalacom®, Pharmacia Inc., Peapack, NJ, 
USA), brimonidine 0.2% (Combigan™, Allergan Inc., Irvine, 
CA, USA), travoprost 0.004% (Duotrav®, Alcon Inc., Fort 
Worth, TX, USA), or bimatoprost 0.03% (Ganfort®, Allergan 
Inc., Irvine, CA, USA) (Frampton 2006).
Fixed combinations of glaucoma medications offer 
numerous advantages for patients requiring multi-drug 
regimens. Most important is enhanced patient compliance. 
Fixed combinations allow reduction of the number of drops 
instilled per day and bottles of medication purchased thus 
overall cost to the individual and the time commitment for 
drop instillation. There is less confusion with drop regime, 
particularly for the older patient. There is no washout effect 
which arises from rapid instillation of multiple medications 
(Chrai et al 1974). Exposure to preservatives is minimized, 
thus reducing subclinical ocular surface inﬂ  ammation and 
glaucoma ﬁ  ltering surgery failure rates (Broadway et al 
1994). However, in some patients, concomitant therapy may 
be required over ﬁ  xed dosing for more individually tailored 
IOP control.
This review focuses on the efﬁ  cacy and safety proﬁ  le 
of ﬁ  xed combination brimonidine tartrate 0.2% and timolol 
maleate 0.5% ophthalmic solution for the treatment of 
glaucoma and ocular hypertension (OH).
Pharmacology – mechanism 
of action
Fixed combination brimonidine/timolol (FCBT) con-
sists of two active substances: brimonidine tartrate 
2.0 mg/mL (1.3 mg brimonidine free base) and timolol 
maleate 6.8 mg/mL (5.0 mg timolol) (MIMS 2007).
Brimonidine tartrate
Brimondine tartrate is a potent and highly selective 
α2-adrenergic agonist, compared with apraclonidine or cloni-
dine (Burke and Schwartz 1996; Cantor 2000) thus reducing 
mydriasis, lid retraction, and vasoconstriction. It is suggested 
that brimonidine lowers IOP by reducing aqueous humor pro-
duction (Larsson 2001) and enhancing uveoscleral outﬂ  ow 
(Serle et al 1991; Toris et al 1995). In addition, brimonidine 
has exhibited neuroprotective activity in experimental neu-
ronal injury models, including light-induced photoreceptor 
damage (Wen et al 1996), optic nerve crush injury (Yoles 
et al 1999), acute retinal ischemia (Villegas-Perez et al 2000), 
and ocular hypertensive retinas (WoldeMussie et al 2001). 
In vivo evidence for neuroprotection is minimal. Reduced 
retinal nerve ﬁ  ber layer damage after brimonidine 0.2% 
compared with timolol 0.5% has been found in OH patients 
over 1 year (Tsai and Chang 2005). Putative mechanisms 
of neuroprotection include increase in neurotrophic factors, 
thus enhancing retinal ganglion cell survival or activation of 
presynaptic α2-receptors with inhibition of neurotransmitter 
release in particular glutamate. Brimonidine has a rapid onset 
of action, with peak ocular hypotensive effect at 2 hours 
post-dosing. The duration of effect is 12 hours or greater.
Timolol maleate
Timolol maleate is a nonselective β-adrenergic antagonist 
that does not have signiﬁ  cant intrinsic sympathomimetic, 
direct myocardial depressant or local anesthetic (membrane 
stabilizing) activity. The precise mechanism of action of 
timolol in IOP lowering is not fully elucidated, but the pre-
dominant action relates to suppression of aqueous secretion 
(Kiland et al 2004). Onset of action is 20 minutes postdosing, 
with peak effect at 1–2 hours. Signiﬁ  cant lowering of IOP 
has been maintained as long as 24 hours.
The IOP lowering efﬁ  cacy of brimonidine has been 
demonstrated in animal models (Burke and Potter 1996), 
and in human subjects with normal IOP (David et al 1995), 
ocular hypertension, or glaucoma (Derick et al 1997). 
Several large clinical trials have also established the efﬁ  cacy 
of brimonidine compared with timolol. The Brimonidine 
Study Group (Schuman 1996; Katz et al 1999) pooled 
results from Brimonidine Study Groups 1 (Schuman et al 
1997) and 2 (Le Blanc et al 1998), 2 large multi-center, 
randomized, double masked, trials of 12 months’ duration. 
Among 837 patients with glaucoma (61%) or OH (39%), Clinical Ophthalmology 2008:2(3) 547
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both brimonidine 0.2% twice daily and timolol 0.5% twice 
daily signiﬁ  cantly reduced mean IOP (p   0.001) from 
baseline levels at every subsequent follow-up visit, both 
at peak (2 hours post dose) and trough times (12 hours 
post dose). Mean changes from baseline IOP ranged from 
5.0–6.2 mmHg in the brimonidine group (p   0.001) and 
5.8–6.5 mmHg in the timolol group (p   0.001). Overall, 
brimonidine showed efﬁ  cacy comparable to than of timolol, 
and is a safe, effective long-term IOP-lowering agent 
(Schuman 1996; Melamed et al 2000).
Javitt et al evaluated the efﬁ  cacy of brimonidine 0.2% 
twice daily and timolol 0.5% twice daily in 211 POAG and 
OH subjects (Javitt et al 2000). Subjects were naïve to treat-
ment, thus eliminating possible β-blocker responsiveness and 
tolerability found in other studies where subjects had responded 
to β-blockers (Schuman 1996). The overall mean decrease in 
IOP was 6.5 mmHg with brimonidine and 6.2 mmHg with 
timolol over 4 months. These rates were comparable with 
other studies where the inherent selection bias described above 
could be an issue (Schuman 1996). Approximately 30% of 
each group did not achieve clinical success.
Van der Valk et al performed a meta-analysis of random-
ized clinical trials of all commonly used glaucoma agents 
for POAG or OH subjects (van der Valk et al 2005). In this 
study, only single agents were evaluated. For brimonidine 
0.2% twice daily, the pooled 1-month relative mean IOP-
lowering effect from baseline was –25% at peak and –18% 
at trough levels. For timolol 0.5% twice daily, the values 
for relative mean IOP-lowering from baseline were –27% 
(peak) and –26% (trough). Greatest IOP lowering effect at 
peak was found with bimatoprost at –33%, and at trough 
was travoprost at –29%. This meta-analysis concluded that 
bimatoprost, travoprost, latanoprost, and timolol are the most 
effective IOP-reducing agents in POAG and OH patients (van 
der Valk et al 2005).
Concomitant brimonidine 
and timolol therapy
Studies of concomitant brimonidine 0.2% and timolol 0.5% 
have shown additive IOP-lowering effects. Larsson observed 
that the reduction in aqueous humor production (58.9%) and 
IOP (34.7%) was greater after combined brimonidine and 
timolol, than timolol (reduced aqueous humor production 
49.9% and IOP 22.9%) or brimonidine (reduced aqueous 
humor production 33.1% and IOP 20.3%) monotherapy 
(Larsson 2001). Yuksel et al also demonstrated additive IOP-
lowering effects of adjunctive brimonidine over 2 days (Yuksel 
et al 1999). POAG or pseudoexfoliative glaucoma subjects 
(n = 15) on timolol twice daily and IOP of  22 mmHg in at 
least one eye, were randomized to adjunctive brimonidine 
0.2% daily or placebo. A statistically signiﬁ  cant decrease in 
IOP at each time interval (1, 2, 4, 6, and 8 hours post dose at 
day 1 and 2) was found compared with the placebo/timolol 
group (p   0.05). Maximum IOP decrease of 7.26 mmHg 
was documented at 4 hours with concomitant therapy. Overall 
additional maximum IOP-lowering effect of brimondine 0.2% 
daily administered adjunctively with timolol twice daily was 
19.23% (Yuksel et al 1999).
Another similar study (Arici et al 2002) evaluated the 
effect of adjunctive brimonidine in timolol-treated subjects 
over a longer time period of 3 weeks. IOP reduction of 
5.1 mmHg (21.2%), 5.9 mmHg (24.5%), and 5.7 mmHg 
(23.6%) at weeks 1, 2, and 3 respectively was found. 
Centofanti et al evaluated unﬁ  xed combination of timolol and 
brimonidine on timolol uncontrolled glaucomatous patients 
(Centofanti et al 1999). IOP further decreased by 16.1% and 
24.7% after 1 and 3 months respectively with adjunctive bri-
monidine 0.2% twice daily. In a larger study of 552 subjects 
with POAG or OH and IOP  20 mmHg in each eye, adjunc-
tive brimonidine also signiﬁ  cantly lowered IOP when added 
to any pre-existing drop regimen (Lee and Gornbein 2001).
Fixed combination 
brimonidine/timolol trials
There are a small number of studies evaluating ﬁ  xed combi-
nation brimonidine 0.2%/timolol 0.5% (FCBT). The Combi-
gan Study Groups I and II pooled data from two identically 
designed multicenter, randomized, double masked, parallel-
group trials. Both studies evaluated FCBT twice daily versus 
monotherapy with the individual components; brimonidine 
0.2% 3 times daily or timolol 0.5% twice daily. Data at 
3 (Craven et al 2005) and 12 (Sherwood et al 2006) months 
were published. Twelve-month data are discussed here.
Eligible subjects were  18 years and required bilateral 
treatment for POAG or OH. Washout period was up to 
4 weeks depending on type of IOP-lowering medication at 
baseline. Baseline IOP after wash-out was 22–34 mmHg in 
each eye, with no greater than 5 mmHg difference between 
eyes. Best corrected visual acuity was 20/100 or better 
in both eyes. Subjects with active ocular disease, function-
ally signiﬁ  cant or progressive visual ﬁ  eld loss in the previous 
year, abnormally low or high blood pressure or pulse rate, 
or contraindications or sensitivity to any component of the 
study treatment were excluded.
At the baseline visit, IOP was measured at 0800, 1000, 
1500, and 1700 hours. Patients were then randomly assigned Clinical Ophthalmology 2008:2(3) 548
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to 1 of 3 treatment groups using a 1:1:1 allocation of FCBT:
timolol:brimondine. Patients self-instilled 1 drop of the 
appropriate study medication into both eyes 3 times daily, 
with a vehicle solution in the afternoon if randomized to the 
brimonidine/timolol or timolol group. Follow-up visits were 
scheduled at weeks 2 and 6 and at months 3, 6, 9, and 12. 
IOP was measured at 0800, 1000, 1500, and 1700 at these 
visits except the 9-month visit when IOP was measured at 
0800 and 1000.
Of 1159 patients enrolled in the study, 385 subjects 
received FCBT, 382 subjects brimonidine, and 392 
subjects timolol. A total of 833 patients (71.9%) completed 
12 months’ treatment. Discontinuation rates were greatest 
in the brimonidine-treated group (169/1159) compared with 
the FCBT (99/1159) or timolol (58/1159) treated groups. 
Demographic characteristics were similar between groups, 
except more females in the brimonidine-treated group. Mean 
age was 62.6 years (29–89 years), 75.8% were white.
The mean IOP at the 0800, 1000, and 1500 measurements 
at baseline were similar between groups. At 1700, mean base-
line IOP was lower in the FCBT group than the timolol group 
(p = 0.01) or the brimonidine group (p = 0.06). The mean 
decrease from baseline IOP at the 22 measured time points 
ranged from 4.4–7.6 mmHg with FCBT, 2.7–5.5 mmHg 
with brimonidine, and 3.9–6.2 mmHg with timolol. Analyses 
showed a signiﬁ  cantly greater decrease in IOP in the FCBT 
group compared with timolol group at all measurements, 
and brimonidine group at all measurements except the 
1700 measurements, which was 2 hours after the mid-day 
brimonidine dose.
Daytime mean IOP was also lower in the FCBT group 
compared with the timolol group at all measurements 
(p   0.002) and the brimonidine group at 0800, 1000, and 1500 
(p   0.001), and 1700 at week 6 (p = 0.04). Mean daytime 
IOP of  18 mmHg was maintained by 39.5% of the FCBT 
group compared with 14.9% and 21.7% of those treated with 
brimonidine or timolol respectively. A mean daytime decrease 
from baseline IOP of greater than 20% at every follow-up visit 
was signiﬁ  cantly greater in the FCBT group (42.1% of patients), 
than the brimonidine (13.1%) or timolol (27.3%) group.
The distribution of patients across the target pressure 
ranges of  14.0, 14.0–17.5, and  17.5 mmHg favored the 
FCBT group over brimonidine or timolol monotherapy. 
There was a signiﬁ  cantly greater shift towards the lowest 
pressure range ( 14.0 mmHg) in the FCBT group than in 
either of the monotherapy groups (p   0.001).
In summary, this study (Sherwood et al 2006) demonstrated 
that the mean decreases from baseline IOP, mean daytime 
IOP, and mean daytime IOP  18 mmHg were signiﬁ  cantly 
greater in the FCBT group compared with monotherapy of 
its constituent parts. Two-fold increased number of FCBT 
subjects achieved  20% reduction in IOP compared with 
timolol monotherapy, and 3-fold compared with brimonidine 
monotherapy.
Versus concomitant therapy 
with the individual components
The Brimonidine/Timolol Fixed Combination Study Group 
(Goni et al 2005) evaluated the efﬁ  cacy and safety of FCBT 
twice daily compared with unﬁ  xed concomitant use of 
brimonidine and timolol each given twice daily. Meth-
odology of this randomized multi-center double-masked 
parallel group study is similar to that of the Combigan 
Study Group I and II described earlier (Craven et al 2005; 
Sherwood et al 2006). There are a few differences; this 
study (Goni et al 2005) also included patients with chronic 
angle-closure, pseudo-exfoliative or pigmentary glaucoma. 
IOP elevation was of a similar range (22–34 mmHg) but 
only required in at least 1 eye and after  3 weeks of run-
in monotherapy of the investigator’s choice, continuation 
of current monotherapy, or cessation of all but one agent 
if multiple agents used. After baseline IOP measurement 
at hour 0, subjects were randomized into FCBT or con-
comitant groups in 1:1 ratio. Run-in monotherapy was 
discontinued. IOP measurements were taken at hour 0 and 
2 at baseline, weeks 2, 6, and 12.
A total of 355 patients (96%) completed the study. Most 
were white (97.3%) and the majority female (62.8%). Types 
of run-in monotherapy (β-blockers [65.0%], brimonidine 
[15.6%], carbonic anhydrase inhibitor [10.5%], prostaglandin 
analog [7.8%], or other [1.1%] topical medications) were 
statistically similar between groups.
Both FCBT and concomitant therapy showed statistically 
signiﬁ  cant mean IOP reductions from monotherapy treated 
baseline at each follow-up time point (p   0.001) (Goni 
et al 2005). At hour 0 (trough) for each time point (weeks 
2, 6, 12), the mean IOP reduction from baseline ranged 
from 4.4 to 4.9 mmHg in each treatment group. At hour 2 
(peak) mean IOP reduction ranged from 4.9 to 5.3 mmHg in 
the ﬁ  xed combination group and from 4.7 to 5.3 mmHg in 
the concomitant group. This was not signiﬁ  cantly different 
between groups.
The mean change from baseline compared with hour 0, 
week 12 IOP (the primary efﬁ  cacy endpoint) was –4.9 mmHg 
for both groups, and the upper limit of the 95% conﬁ  dence 
interval (CI) for the difference between groups was 0.79, Clinical Ophthalmology 2008:2(3) 549
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thus demonstrating noninferiority of combination treatment 
compared with concomitant therapy. Mean IOP at follow-up 
measurements ranged from 17.3 to 20.6 mmHg in the FCBT 
group and from 17.1 to 20.5 mmHg in the concomitant group, 
again not signiﬁ  cantly different. Among patients run-in on 
timolol monotherapy, no difference was found between 
treatment groups. Patients run-in on other medications also 
showed similar mean changes from baseline IOP between 
treatment groups.
The percentages of subjects in each treatment group 
who achieved target pressures of  18 mmHg were 
comparable; 33.0% and 37.2% of subjects in FCBT 
and concomitant group respectively at hour 0, week 12, 
and 70.2% and 70.5% at hour 2, week 12. An average 
IOP  17.5 mmHg over all follow-up measurements was 
comparable between treatment groups (29.3% FCBT vs 
29.5% concomitant group).
This clinical trial has thus demonstrated that FCBT is 
noninferior to concomitant therapy. The primary efﬁ  cacy 
endpoint compared baseline with IOP at week 12, where 
washout of previous monotherapy would not have con-
founded results. Measurements for mean change from base-
line IOP, mean IOP at follow-up, and percentage of subjects 
achieving target pressures  18 mmHg, were also statistically 
similar between the two groups.
A more recent randomized controlled trial (Konstas et al 
2007) has evaluated the 24-hour IOP control of FCBT versus 
the combination of its individual components, each dosed 
twice daily, in patients with POAG or OH. After a 6-week 
wash-out period, 28 patients were randomized to FCBT or to 
the unﬁ  xed combination for 3 months and then crossed over 
to the opposite treatment for another 3 months. Twenty-four 
hour IOP measurements (0600, 1000, 1400, 1800, 2200, 
and 0200 hours) were performed after the wash-out period 
and each treatment period. The mean 24-hour IOP was 
24.6 mmHg for baseline, 19.2 mmHg for the FCBT group, 
and 19.2 mmHg for the concomitant group. Both FCBT and 
the unﬁ  xed components showed a signiﬁ  cant IOP reduction 
from untreated baseline (p   0.0001). The two treatment 
groups were statistically equal when compared directly, for 
each individual time point and for the 24-hour IOP curve 
(p   0.05).
Versus dorzolamide/timolol
Dorzolamide hydrochloride is a topical carbonic anhydrase 
inhibitor which was initially developed for use as mono-
therapy. Carbonic anhydrase found in the ciliary processes 
of the eye is inhibited, thus decreasing production of 
bicarbonate and subsequent sodium ﬂ  uid transport. IOP is 
lowered by reducing aqueous secretion. A ﬁ  xed combination 
of timolol maleate 0.5% and dorzolamide hydrochloride 
2% (FCDT) was introduced in 1998. Clinical studies have 
demonstrated comparable efﬁ  cacy of the FCDT product 
with concomitant administration (Strohmaier et al 1998), 
and greater than either of its component parts (Boyle et al 
1998; Clineschmidt et al 1998).
Centofanti et al (2000) explored the IOP-lowering effect 
of adding brimonidine 0.2% or dorzolamide 2% on 28 
patients (right eye of each subject) with advanced POAG and 
a visual ﬁ  eld mean defect of –10 to –16 dB. Patients were 
on timolol 0.5% twice daily treatment. Adjunct medication 
was administered in a masked fashion 2 hours after timolol 
dose, and IOP measured at 2-hour intervals. Adjunctive 
treatment was crossed over 3 weeks later, and IOP measured 
as for visit 1. Mean pretreatment IOP for all the group was 
19.36 mmHg. As an adjunct to topical β-blockers, 1 drop 
of brimonidine 0.2% was more effective (p   0.05) than 
1 drop of dorzolamide 2% in lowering IOP at 4 hours (mean 
IOP decrease 28.4 mmHg vs 17.6 mmHg; p = 0.04) and at 
8 hours (mean IOP decrease 35.5% vs 21.6%; p = 0.04). 
Safety proﬁ  les were not published.
The Alphagan/Trusopt Study Group (Simmons et al 
2001) randomly assigned 106 POAG or OH patients using 
a nonselective or selective topical β-blocker to receive bri-
monidine 0.2% twice daily or dorzolamide 2% 3 times daily 
as adjunctive therapy for 3 months. IOP was inadequately 
controlled on β-blocker monotherapy (IOP 18–34 mmHg 
in each eye). Cross over of study medication occurred if 
the target 15% reduction in IOP at peak drug effect was 
not achieved after 1 month. Most patients were on timolol 
(61.3%), and most had POAG (61.3%).
Mean baseline IOP (with β-blocker monotherapy) was 
comparable between treatment groups (21.56 mmHg in the 
brimonidine vs 20.89 mmHg in the dorzolamide group, 
p = 0.284) (Simmons et al 2001). At 1 month, the mean 
IOP reduction at peak effect was signiﬁ  cantly greater in 
the brimonidine group (5.95 mmHg, 27.6%) than in the 
dorzolamide group (4.11 mmHg, 19.7%; p = 0.007). This 
was not statistically different at 3 months (6.39 mmHg with 
brimonidine and 4.06 mmHg with dorzolamide, p = 0.059). 
However, among patients who had achieved the target IOP 
reduction at month 1, a greater percentage of brimonidine-
treated patients (77.8%, 28/36) met the target IOP at month 
3 than did dorzolamide-treated subjects (44.4%, 12/27, 
p = 0.007). Additionally, 2-fold increased rates of IOP reduc-
tion of  25% at month 3 were seen in the brimonidine-treated Clinical Ophthalmology 2008:2(3) 550
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group (61.1%) compared with the dorzolamide-treated group 
(33.3%, p = 0.029). These two trials (Centofanti et al 2000; 
Simmons et al 2001) suggest that brimonidine is more pow-
erful and better sustained in reducing IOP than dorzolamide 
when added to β-blocker treatment.
Two randomized, observer-masked, multi-center trials 
have compared the efﬁ  cacy of FCDT with the concomitant 
administration of brimonidine 0.2% twice daily and timolol 
0.5% twice daily (Sall et al 2003; Solish et al 2004). Sall 
et al enrolled 293 participants with POAG or OH with IOP 
 22 mmHg at hour 2 in at least 1 eye after an open-label 
3-week timolol (0.5% twice daily) run-in period (Sall et al 
2003). Subjects were randomized to receive FCDT twice 
daily or the concomitant use of brimonidine twice daily and 
timolol twice daily for 6 months. At month 3, hour 2, the 
mean change in IOP in the FCDT group was –5.04 mmHg 
versus –5.41 mmHg in the brimonidine and timolol group, 
with a treatment difference of 0.36 mmHg (95% CI of –0.42 
to 1.14 mmHg). At all other observed time points treatments 
were considered comparable as the 95% CI of the treatment 
difference was within ± 1.5 mmHg. This study was observer-
masked to maintain drop stability.
Solish et al aimed to replicate the results of the 
aforementioned study (Sall et al 2003) using a larger 
cohort of 492 patients with POAG or OH, and in addition 
pseudoexfoliative or pigmentary glaucoma (Solish et al 
2004). Run-in with timolol 0.5% was conducted in a similar 
manner to the initial study (Sall et al 2003). Study duration 
was 3 months. At month 3, hour 2, the mean change from 
baseline IOP among the FCDT group was –4.30 mmHg 
versus –5.27 mmHg in the brimonidine and timolol group, 
with a treatment difference of 0.97 mmHg (95% CI 
0.40, 1.53). The point estimate (0.97 mmHg) was within 
the ±1.5 mmHg comparability boundary, although the 95% 
CI of 0.40, 1.53 exceeded this boundary. At month 3, hour 
0, the mean change in IOP from baseline was –3.31 mmHg 
compared with 3.52 mmHg for the brimonidine + timolol 
group. The treatment difference was 0.21 mmHg with 95% 
CI of –0.39 to 0.82 mmHg (Solish et al 2004). As IOP-
lowering effects on all other time points were similar, the 
authors concluded that the difference found at month 3, hour 
2, was not likely to be meaningful clinically and FCDT was 
comparable to concomitant brimonidine and timolol.
A more recent but smaller prospective, multi-center, 
randomized, cross-over trial has compared FCBT with FCDT 
given twice daily in subjects  18 years with POAG (n = 16) 
or OH (n = 14) in at least 1 eye (Arcieri et al 2007). Other 
inclusion criteria were baseline IOP of 22–34 mmHg (not on 
medications) and best corrected visual acuity of 20/200 or 
better. Of eyes not included in the study, IOP must have been 
controllable on no medication or on the study medication. 
After wash-out of previous treatment, subjects were random-
ized to FCBT or FCDT for the ﬁ  rst 4-week treatment period. 
Subjects then were again washed for 4 weeks and started on 
the opposite medication for the second 4-week period. IOP 
was measured at 0800, 1200, and 1600 hours at each baseline 
and at the end of each treatment period.
The baseline mean diurnal IOP for all 30 subjects (30 
eyes) was 22.9 mmHg. No difference was found in the mean 
diurnal IOP after 4 weeks of therapy (15.0 mmHg for FCBT 
and 15.4 mmHg for FCDT, p = 0.510). No difference was 
found in the mean diurnal IOP reduction (7.8 mmHg for 
FCBT and 7.4 mmHg for FCDT, p = 0.430). Both ﬁ  xed 
combinations signiﬁ  cantly reduced IOP compared with 
baseline (p   0.00001). This study suggests that FCBT and 
FCDT have similar efﬁ  cacy in POAG or OH. Patients were 
not masked to their study therapy, but investigators were 
masked. Investigators attempted to limit this potential bias 
through a randomizing crossover design.
Versus latanoprost
Latanoprost is an F2α-prostaglandin analog and is highly 
selective for the FP receptor (Stjernschantz and Resul 1992). 
It reduces IOP levels by increasing uveoscleral outﬂ  ow with 
little or no effect on aqueous humour production (Toris et al 
1993; Ziai et al 1993). Studies have shown that latanoprost 
daily is more effective than timolol twice daily in reducing 
IOP (Alm and Stjernschantz 1995; Camras 1996; Mishima 
et al 1996). Latanoprost has also been shown to be more 
effective than brimonidine 0.2% twice daily (Stewart et al 
2000a; Stewart et al 2001). In a retrospective review of 
clinical ﬁ  les, Stewart et al compared the efﬁ  cacy of latano-
prost 0.005%, brimonidine 0.2%, or dorzolamide 2% when 
added to a topical β-blocker for at least 3 months in patients 
with POAG or OH (Stewart et al 2000b). Participants on 
latanoprost (n = 50) showed an IOP of 16.7 mmHg and 
reduction from baseline of –6.3 mmHg. Those on brimoni-
dine (n = 24) showed an IOP of 17.4 mmHg and reduction 
from baseline of –4.2 mmHg, p   0.001 and on dorzolamide 
(n = 67) an IOP of 20.1 mmHg and reduction of –3.1 mmHg, 
p   0.001. A signiﬁ  cant difference was observed between 
groups in success rates (deﬁ  ned as reduction in IOP   
3 mmHg); latanoprost 70%, brimonidine 58%, dorzolamide 
40%, p = 0.008 (Stewart et al 2000b).
To date, there are no published studies of FCBT versus 
ﬁ  xed combination latanoprost/timolol (FCLT). However, Clinical Ophthalmology 2008:2(3) 551
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2 studies have compared FCLT daily versus concomitant 
brimonidine and timolol twice daily (Stewart et al 2003; 
Garcia-Sanchez et al 2004). Stewart et al randomized 32 
subjects with POAG or OH to FCLT or concomitant brimon-
dine and timolol twice daily (Stewart et al 2003). IOP in the 
study eye after 1 month of timolol administered twice daily 
ranged from 21 to 34 mmHg. Treatment was crossed-over 
after 6 weeks. IOP was measured every 2 hours between 0800 
and 2000 hours at baseline and at the end of each treatment 
period. Compared with timolol alone (20.9 mmHg) mean 
diurnal IOP decreased to 17.9 mmHg when patients were 
treated with ﬁ  xed combination timolol/latanoprost, and 
decreased to 19.0 mmHg when patients were treated with 
brimonidine and timolol (p = 0.02). When treatment groups 
were compared directly, a greater statistical reduction in IOP 
was found among those using FCLT. The greatest difference 
in IOP between treatment groups was at 12 hours post dosing. 
This study suggests that FCLT given in the evening reduces 
the mean daytime diurnal IOP more than brimonidine and 
timolol given concomitantly twice daily.
A multi-center European study evaluated IOP in 325 
patients with POAG or OH on FCLT given in the morning or 
concomitant brimonidine/timolol given twice daily (Garcia-
Sanchez et al 2004). For inclusion, subjects had IOP  21 
mmHg on monotherapy, or  16 mmHg on dual therapy. At 
baseline, mean diurnal IOP was 26.4 mmHg for the FCLT 
group and 26.5 mmHg for the concomitant brimonidine/timo-
lol group. After 6 months, mean diurnal IOP was signiﬁ  cantly 
lower in the FCLT group (16.9 mmHg) compared with the 
brimonidine/timolol group (18.2 mmHg), p   0.001. FCLT 
administered once daily is both more effective and better 
tolerated than dosing twice daily with unﬁ  xed brimonidine/
timolol concomitant treatment.
Indeed, in a large post-hoc analysis, addition of brimoni-
dine to a nonselective β-blocker reduced IOP by an additional 
15.5% (3.61 mmHg, p   0.001). When brimonidine was 
added to latanoprost, the mean additional IOP reduction was 
2-fold at 32.2% (5.89 mmHg, p   0.001) (Lee and Gornbein 
2001). Thus, studies evaluating concomitant latanoprost and 
brimonidine versus FCBT may also be helpful in determining 
IOP lowering efﬁ  cacy. The combination of a prostaglandin 
analog with an α-agonist will also eliminate the cardio-
pulmonary adverse effects of timolol.
Pharmacokinetics 
Both brimonidine 0.2% and timolol 0.5% are rapidly absorbed 
into ocular tissues after topical application. After FCBT, 
the terminal half-life in aqueous (rabbits) for brimonidine 
was 1.23 hours, and for timolol 1.12 hours. Peak plasma 
concentration (Cmax) and area under the plasma concentration 
time curve (0–12 hours) (AUC) were not significantly 
different between FCBT and the respective monotherapies. 
Cmax values were 32.7 pg/mL and 0.41 ng/mL, AUC values 
128 pg.h/mL and 2.92 ng.h/mL, and time to Cmax (Tmax) values 
1.28 hours and 2.42 hours for brimonidine and timolol, 
respectively, after FCBT twice daily administration for 7 
days to 16 healthy volunteers. Plasma brimonidine concen-
tration after 2 weeks and 12 months of FCBT twice daily 
was 61.0 pg/mL and 56.2 pg/mL in one study and 50.6 pg/ml 
and 51.5 pg/ml for the other study, respectively. Plasma 
timolol concentration was 0.74 ng/mL and 0.55 ng/mL in 
one study, and 0.50 ng/mL and 0.54 ng/mL for the other 
study, respectively. These concentrations were lower than 
those for respective monotherapies in both studies. Also, 
concentrations did not increase over time.
When systemically absorbed, brimonidine (29%) and 
timolol ( 10%) are not extensively bound to human plasma 
protein. Brimonidine and timolol are partially metabolized 
by the liver (mediated by aldehyde oxidase and cytochrome 
P450 for brimonidine), and primarily excreted by the kidneys. 
After FCBT for 7 days, plasma elimination half-life value was 
2.43 hours for brimondine and 7.32 hours for timolol.
Safety
Tolerability and treatment-related adverse events proﬁ  le of 
FCBT were evaluated simultaneously in most of the larger 
studies mentioned. Use of FCBT was associated with fewer 
side effects than brimonidine alone (p = 0.006), but more 
than timolol alone (p   0.001) (Sherwood et al 2006). 
In this study, 28.1% of subjects discontinued treatment; 
16.6% had adverse events, 4.6% due to poor efﬁ  cacy, and 
7.0% other reasons. FCBT subjects had a lower incidence 
of 1+ treatment-related adverse events (53.0% vs 62.8%), 
discontinuations due to adverse events (14.3% vs 30.6%), 
and at least a 1-grade increase in severity in biomicroscopic 
ﬁ  ndings (54.8% vs 62.8%) compared with the brimonidine-
treated group. Compared with the timolol-treated group, 
higher rates of 1+ treatment-related adverse events (53.0% 
vs 40.8%) and discontinuations due to adverse events (14.3% 
vs 5.1%) were found.
Of individual adverse events, the brimonidine group had 
higher rates of conjunctival hyperemia (22.8% vs 14.5%), 
eye pruritus (11.0% vs 5.5%), allergic conjunctivitis (9.4% 
vs 5.2%), conjunctival folliculosis (9.2% vs 4.9%), oral dry-
ness (9.2% vs 2.1%), and conjunctival allergy/inﬂ  ammation 
(39.8% vs 26.0%) compared with the FCBT group (Sherwood Clinical Ophthalmology 2008:2(3) 552
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et al 2006). Ocular stinging was more common with FCBT 
than with brimonidine alone (p = 0.03). The timolol group 
had signiﬁ  cantly less conjunctival hyperemia (7.4%), eye 
pruritus (2.8%), allergic conjunctivitis (0.3%), conjunctival 
folliculosis (1.8%), oral dryness (0.5%), and conjunctival 
inﬂ  ammation (12.0%) than FCBT, and similar rates of ocu-
lar stinging (6.6%). Similar adverse events proﬁ  le has been 
documented in studies directly comparing brimonidine with 
timolol (Schuman 1996; Katz et al 1999).
When compared with concomitant brimonidine/timolol, 
FCBT group had higher incidence of adverse events (30.3% 
vs 24.6%) or 1+ treatment-related adverse events (20.2% vs 
14.2%), although neither was statistically signiﬁ  cant (Goni 
et al 2005). Ocular pain, pruritus, and headache were reported 
most often. No signiﬁ  cant differences between groups were 
found for discontinuation of treatment from treatment-related 
adverse events, or biomicroscopic or ophthalmoscopic ﬁ  nd-
ings between groups (Goni et al 2005).
Reduced allergy levels with FCBT could be attributed 
to twice daily dosing as opposed to 3 times daily for brimo-
nidine monotherapy, thus reducing brimonidine exposure. 
Alvarado postulated that the difference can be explained at 
a cellular level (Alvarado 2007). Adrenergic agonists reduce 
cell volume, increase intercellular ﬂ  uid ﬂ  ow, and potentially 
allow greater access of proinﬂ  ammatory mediators to the 
subconjunctival space. The addition of a β-blocker counter-
acts the cell volume effects of adrenergic agonists (Alvarado 
2007). Interestingly, Osborne et al noted a signiﬁ  cant delay 
in brimonidine-induced allergy among patients previously 
receiving timolol maleate (Osborne et al 2005). In this 
study, brimonidine was discontinued due to allergy on 73 
per 100,000 patient treatment days, a far higher frequency 
than for other preparations. Patients with allergy to both 
brimonidine and another preparation (timolol, dorzolamide, 
or latanoprost) had a shorter interval between the ﬁ  rst and 
second allergy if brimonidine allergy occurred ﬁ  rst.
Reported systemic effects of FCBT in key studies 
were few and consistent with the individual components 
(Sherwood et al 2006). Small but statistically signiﬁ  cant 
changes in heart rate (2–3 beats per minute) and blood pres-
sure were found in the FCBT and timolol-treated group. 
Two patients from the timolol group were hospitalized due 
to serious treatment-related complications; one patient with 
respiratory distress, the other with tachycardia, nausea, and 
sweating (Sherwood et al 2006). No systemic adverse events 
were noted for brimonidine.
Well-recognized problems of topical timolol identiﬁ  ed 
from other studies include cardiac failure, bradycardia 
(Schuman 1996; Katz et al 1999) and heart block, 
bronchospasm and respiratory arrest. Confusion, headaches, 
reduced exercise tolerance, nocturnal hypotension, and 
impotence, have also been reported (Stewart and Garrison 
1998). The most frequent systemic side effects reported 
from brimonidine were fatigue and dry mouth (Derick et al 
1997). Some studies have observed statistically signiﬁ  cant 
decreases in mean blood pressure without clinical symptoms 
with brimonidine 0.2% and 0.5% treatment (Derick et al 
1997). Differences to other studies (Craven et al 2005; Goni 
et al 2005; Sherwood et al 2006) in systemic side effect 
proﬁ  le may be explained by selection bias, as patients with 
a history of adverse events with β-blocker therapy, previous 
poor response to β-blockers, or systemic contraindications 
to the medication were excluded. Brimonidine use is not 
limited by pulmonary and cardiovascular contraindications. 
Brimonidine does not exhibit tachyphylaxis in clinical trials 
from 12 months (Nordlund et al 1995; Schuman 1996; Serle 
1996) up to 4 years (Adkins 1998; Cantor 2000).
Compared with FCDT, FCBT has significantly less 
stinging and burning on application (p = 0.027) (Arcieri 
et al 2007). This ﬁ  nding is supported by a single-center, 
randomized, paired-eye study of 30 subjects without sig-
niﬁ  cant ocular surface disease (Chan et al 2007). FCBT was 
signiﬁ  cantly more comfortable than FCDT on instillation 
(p   0.0001), but not at 5 minutes. This is also in agreement 
with earlier studies (Sall et al 2003; Solish et al 2004) where 
FCDT treatment was compared with concomitant brimoni-
dine/timolol. Over a 6-month study period, ocular stinging 
and burning, and dysgeusia were reported more frequently 
with FCDT (Sall et al 2003). The study by Arcieri et al may 
be too short in duration to allow for development of allergic 
effects and the study not powered sufﬁ  ciently to detect a 
difference (Arcieri et al 2007).
Compared with FCLT, concomitant brimonidine/timolol 
had a similar adverse event proﬁ  le on one (Stewart et al 2003) 
but not in another study (Garcia-Sanchez et al 2004). In the 
latter study, treatment-related adverse events were greater 
in the FCBT group (18.6% vs 7.3%). Allergy was found in 
2.4% of FCLT patients compared with 7.8% of concomitant 
brimonidine/timolol group. Higher discontinuation rates 
were found with FCBT (17.3% vs 6.0%), with most subjects 
discontinuing treatment because of adverse events (10.8% 
vs 1.8%).
Dosage and administration
FCBT is indicated for the reduction of IOP in patients with 
POAG or OH who are insufﬁ  ciently responsive to topical Clinical Ophthalmology 2008:2(3) 553
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β-blockers. The recommended dosage is 1 drop into the 
affected eye twice daily.
Contraindications to FCBT include hypersensitivity to the 
individual components, monoamine oxidase inhibitor use, 
bronchospasm, bronchial asthma, severe chronic obstructive 
pulmonary disease, sinus bradycardia, second or third degree 
atrioventricular block, or overt cardiac failure or cardiogenic 
shock (MIMS 2007).
Precautions with FCBT use include cardiac, renal or 
hepatic failure, depression, cerebral or coronary insufﬁ  -
ciency, severe peripheral and central circulatory disorders, 
Prinzmetal angina, Raynaud’s phenomenon, orthostatic 
hypotension, thromboangiitis obliterans, spontaneous hypo-
glycemia (diabetes), hyperthyroidism, myasthenia gravis, 
general anesthesia, history of atopy and anaphylaxsis, and 
use in neonates or pregnancy (MIMS 2007).
Conclusion
Clinical trials and utilization studies have demonstrated 
that many patients with POAG or OH require multiple 
medications to achieve adequate control of IOP (Fechtner 
and Realini 2004). Trials have established IOP additivity 
of concomitant brimonidine 0.2% 2 or 3 times daily and 
timolol 0.5% twice daily. FCBT has been shown in large 
multi-center randomized trials to be more efﬁ  cacious in 
lowering IOP than monotherapy with its constituent parts. 
It is noninferior to unﬁ  xed concomitant use of brimonidine 
and timolol each given twice daily. FCBT or concomitant 
brimonidine/timolol are as efﬁ  cacious as FCDT. However, 
as adjuncts to timolol treatment, brimonidine is more effec-
tive in lowering IOP than dorzolamide. Compliance issues 
with dorzolamide include stinging on application, 3 times 
daily dosing, and excessive somnolence and fatigue. FCLT 
provides greater efﬁ  cacy than concomitant timolol and bri-
monidine. Unfortunately no published studies have evaluated 
FCLT compared with FCBT.
Local and systemic adverse events for FCBT were pre-
dictable and based on that of the individual components used 
alone and concomitantly. No unexpected or serious adverse 
events associated with the ﬁ  xed combination were reported 
in the major trials of FCBT. However, this may reﬂ  ect selec-
tion bias, as patients with a history of adverse events with 
β-blocker therapy, previous poor response to β-blockers, or 
systemic contra-indications to the medication were excluded. 
FCBT may be advantageous over FCDT with respect to ocu-
lar tolerability and comfort, hence enhanced compliance.
In summary, FCBT is a safe and efﬁ  cacious treatment for 
elevated IOP for patients with POAG or OH uncontrolled 
on monotherapy. Studies evaluating FCBT compared with 
FCLT and compared with concomitant brimonidine/latano-
prost are required.
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